Forefront Wealth Management Inc. Buys New Shares in Pfizer Inc. (NYSE:PFE)

Forefront Wealth Management Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,891 shares of the biopharmaceutical company’s stock, valued at approximately $554,000.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer during the 4th quarter valued at $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer in the 4th quarter worth about $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1 %

Shares of NYSE PFE opened at $26.20 on Friday. The firm’s 50 day moving average price is $26.17 and its 200-day moving average price is $27.05. The company has a market cap of $148.61 billion, a PE ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PFE. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.